Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.50 |
| ▸ | FNTB | P49356 | 5/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711099 | 0.86 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL6712743 | 0.85 | FNTA (0.46) | FNTAFNTBPGGT1B | |
| SCHEMBL6712621 | 0.85 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL6709731 | 0.85 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL6712609 | 0.84 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL6708786 | 0.84 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL6710999 | 0.84 | MAPKAPK2 (0.55) | — | |
| SCHEMBL6711334 | 0.84 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL6708647 | 0.84 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL6709677 | 0.84 | MAPT (0.48) | FNTAFNTBUSP2SMN1; SMN2PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | PIERRE FABRE MEDICAMENT (FR) | 2004-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | CBR3, CBR1, HCCS | FNTA 194/4885FNTB 48/4885USP2 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.